PTPRC and acute myeloid leukemia: Further, in vivo efficacy study in AML xenograft mice model demonstrated that treatment with HSANPs‐PEI@EZH2siRNA and free EZH2siRNA significantly reduced CD45+/CD11b+ in AML cells from 58.1% to 31% and 31.2%, respectively, in peripheral blood circulation and from 9.64% to 0.11% and 0.49% in bone marrow fractions, respectively (Figure 6b).